Replies to post #213962 on Biotech Values

[ghmm]

ADHD / Arcturus:

Yes I did listen. I was intrigued by the low valuation of the company given they have a few partnerships with reputable companies. They are basically a preclinical company (thus the reverse merger) other than the ABUS HBV program. I got the impression they are in need of funds to get to meaningful data. They were light on details as far as their royalty interests (I didn't look to see if they are anywhere) and if one googles the company there website doesn't even show up on the first couple pages anyway (They do have a website but I wonder if it was just put together http://arcturusrx.com/).

Here is the slide deck used:
https://www.sec.gov/Archives/edgar/data/1566049/000114420417050441/v476068_ex99-3.htm

The transcript is here:
https://seekingalpha.com/article/4110377-alcobra-adhd-ceo-david-baker-arcturus-merger-alcobra-conference-call-transcript?part=single

I am tempted to look closer as buying via ADHD may be a cheap entry because I think they are getting a nice chunk of equity. I wonder if the people in ADHD were looking for something better (I believe there is an activist involved) with the sell off so perhaps it won't go through?

Edit:
Here is the Ultragenyx PR on terms (royalties, milestones, additional targets)
http://ir.ultragenyx.com/releasedetail.cfm?releaseid=939100